Uses of Lubilax: - Constipation - Irritable bowel syndrome Irritable Bowel Syndrome with Constipation (IBS-C), Chronic idiopathic constipation, Opioid-induced Constipation (OIC) in adults with chronic non-cancer pain History of mechanical GI obstruction.

Other laxative preparations

Lubiprostone is a locally-acting chloride-channel activator that increases intestinal secretion. In doing so, it increases intestinal motility, thus aiding the passage of stool and relieve the symptoms associated with chronic idiopathic constipation.Lubiprostone acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.

How to use Lubiprostone: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Lubiprostone is to be taken with food. Administration: Should be taken with food. Adult Dose: Oral Chronic idiopathic constipation Adult: 24 mcg bid daily. Irritable Bowel Syndrome With Constipation 8 mcg twice daily. Opioid-Induced Constipation Treatment in patients with chronic noncancer pain 24 mcg bid daily. Hepatic impairment Mild: Dose adjustment not necessary Moderate (Child-Pugh B): Chronic idiopathic or opioid-induced constipation, 16 mcg PO q12hr; irritable bowel syndrome with constipation (IBS-C), no dosage adjustment required Severe (Child-Pugh C): Chronic idiopathic or opioid-induced constipation, 8 mcg PO q12hr; IBS-C, 8 mcg PO q24hr Child Dose: Safety and efficacy not established

There is a possibility of a dose-dependent decrease in the efficacy of Lubiprostone in patients using diphenylheptane opioids.

History of mechanical GI obstruction.

Common - Nausea - Headache - Abdominal pain - Abdominal distension - Diarrhea - Flatulence >10% Nausea (29%),Headache (12%),Diarrhea (11%) 1-10% Edema (3%),Chest discomfort (2%),Peripheral edema (1-3%),Fatigue (2%),Dizziness (3%),Flatulence (4-6%),Abdominal distress (3%),Dyspepsia (2%),Xerostomia (1%),Abdominal pain (4-8%),Loose stools (3%)

Pregnancy category C. It is not known whether lubiprostone is excreted in human milk. Because lubiprostone increases fluid secretion in the intestine and intestinal motility, human milk-fed infants should be monitored for diarrhea. Caution should be exercised when Lubiprostone is administered to a nursing woman.

Precaution: Safety has not been established in pregnant women. Not to be used in patients with severe diarrhoea. Lactation: Unknown whether drug is excreted in breast milk; because lubiprostone increases fluid secretion in the intestine and intestinal motility, monitor breastfeeding infants for diarrhea

Adverse reactions due to overdose may include: nausea, diarrhea, vomiting, dizziness, headache, abdominal pain, flushing/hot flash, retching, dyspnea, pallor, stomach discomfort, anorexia, asthenia , chest discomfort, dry mouth, hyperhidrosis , and syncope.

Store between 15-30° C.

Other laxative preparations

Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine. By increasing intestinal fluid secretion, Lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation.

Pregnancy category C. It is not known whether lubiprostone is excreted in human milk. Because lubiprostone increases fluid secretion in the intestine and intestinal motility, human milk-fed infants should be monitored for diarrhea. Caution should be exercised when Lubiprostone is administered to a nursing woman.